Regulatory Perspectives And Scientific Insights On Biosimilars In India


Shubhangi J. Patil[1*], Rutuja M.Patil[2]

[1]Dept. Of Pharmaceutics, KCT's Krishna College of Pharmacy, Karad Maharashtra. 415539

[2]Dept. Of Pharmaceutics, KF's Jayawant Institute of Pharmacy, Karad Maharashtra. 415539

Email: patil.shubhangi13@gmail.com

Abstract

Biologics have transferred the management of chronic and life threatening diseases such as cancer, autoimmune disorder and Diabetes. Biosimilars are playing an important role in strengthening India's healthcare system by providing cost-effective biologic therapies and improving patient access. With support from the Central Drugs Standard Control Organization and Department of Biotechnology, India is emerging as a key centre for biosimilar research and production, helping make healthcare more affordable and widely available. This review looks at how biosimilars are changing in India, with a focus on regulatory frameworks, development challenges, market dynamics, and clinical considerations. It brings up important topics like immunogenicity, interchangeability, pharmacovigilance, and how doctors feel about it. The review also looks at how biosimilars affect the economy by making healthcare more affordable and easier to get. Even though a lot of progress has been made, there are still problems like complicated rules, a lack of knowledge, and limited infrastructure. The paper says that biosimilars are at the forefront of changing Indian healthcare and calls for a strategic approach that includes policy changes, more money for biotechnology, and educating all stakeholders. A well-planned shift to biosimilars could make healthcare in India more fair and long-lasting.

Keywords: Biosimilars, Healthcare in India, Biologic drugs, Cost reduction, Chronic illnesses, Regulatory system, CDSC Organization, Industry growth.

1. Introduction

1.1 Biologics and Biosimilars

Biologics are advanced medicines produced using living cells and are commonly used to treat serious conditions such as diabetes, cancer, and autoimmune diseases. Biosimilars are highly comparable versions of these biologic drugs, offering similar safety and therapeutic effects at a lower cost. They play an important role in making these treatments more accessible, particularly in countries like India.

1.2 Importance of Biosimilars Globally and in India

Biosimilars serve as cost-effective substitutes for expensive biologic medicines, helping to lower treatment costs and improve access to therapies for chronic illnesses. In India, pharmaceutical companies like Biocon and Dr. Reddy's Laboratories contribute significantly to the availability of these medicines, supporting improved healthcare access and long-term sustainability (1, 2).

1.3 Burden of Chronic Diseases in India

Chronic diseases such as heart disease, cancer, diabetes, and respiratory conditions are a major health concern in India. As reported by the World Health Organization, they cause around 63% of total deaths, showing their serious impact on public health (3, 4).

1.4 Key Characteristics of Biosimilars

Biosimilars are similar to original biologics with comparable safety and effectiveness. They undergo strict testing and approval, and being more affordable, they help expand access to quality treatments (5, 6).

1.5 Difference Between Biosimilars and Generics

Biosimilars and generics are both designed to provide cost-effective alternatives to original branded medicines. However, they are quite different in terms of how they are made, their molecular structure, and the regulatory standards required for their approval.

Table 1. Difference Between Biosimilars and Generics (7, 8)

Feature	Biosimilars	Generics
Definition	Highly similar versions of approved biologic medicines	Exact copies of small-molecule drugs
Origin	Produced using living organisms such as cells or bacteria	Made through chemical synthesis
Molecular Structure	Large and structurally complex	Small and relatively simple

Feature	Biosimilars	Generics
Identical to reference product	Not identical, but highly similar	Completely identical
Manufacturing Process	Highly complex, based on biotechnology	Simple and well-established chemical methods
Regulatory Requirements	Require extensive analytical, preclinical, and clinical comparability studies	Require only bioequivalence testing
Cost Reduction	Moderate reduction (around 20–40%)	High reduction (up to 80–90%)
Examples	Monoclonal antibodies, insulin products	Paracetamol, ibuprofen

1.6 Central Drugs Standard Control Organization (CDSCO)

The Central Drug Standard Control Organization (CDSCO) functions under the Ministry of Health and Family Welfare of the Government of India and is responsible for regulating drug and pharmaceuticals in the country (9,10).

1.6.1. Key Roles of CDSCO in Biosimilar Regulation

- Market Approval
- Clinical Trial Oversight
- Assessment of Safety and Effectiveness
- Post-Market Monitoring
- Regulatory Compliance

Overall, CDSCO plays a crucial role in confirming that biosimilars are sufficiently similar to their reference biologics before allowing their use in the Indian healthcare system.

1.6.2. Department of Biotechnology (DBT)

The Department of Biotechnology, under the Ministry of Science and Technology, supports biosimilar development in India by providing scientific guidance and promoting research and innovation in the biopharmaceutical sector.

1.6.3. Key Roles of DBT

- Support for Scientific Assessment
- Development of Guidelines
- Technical Advisory Role
- Promotion of Research Capacity

1.6.4. Collaborative Regulatory Mechanism

In India, biosimilars are regulated under a collaborative system between the Central Drug Standard Control Organization (CDSCO) and the department of biotechnology, following the "Guideline on Similar Biologics"

This collaboration ensures:

• Strong scientific evaluation through DBT expertise

• Strict regulatory oversight by CDSCO

• Alignment with global standards set by the World Health Organization and European Medicines Agency

1.6.5. Importance of the Regulatory Framework

- Ensures safety and effectiveness of biosimilar medicines
- Builds confidence among healthcare providers and patients
- Encourages innovation in India's biopharmaceutical sector
- Strengthens India's position in the global biosimilars market (7,8)

2. Guidelines for Similar Biologics (2016, Revised 2019) and Approval Process

The "Guidelines on Similar Biologics" were jointly prepared by the Central Organization Standard Control Organization and the department of biotechnology outline the regulatory route for the development and approval of biosimilars in India. Initially introduced in 2012 and later updated in 2016 and 2019, these guidelines aim to ensure that biosimilars closely match the reference biologic in terms of quality, safety, and therapeutic effectiveness (11,12). The framework is also consistent with international standards, including those

2.1. Analytical Studies

Analytical testing is the first and most important stage in biosimilar development. It involves detailed analysis of physicochemical properties like structure, purity, molecular weight, and glycosylation, along with testing biological activity through specific assays.

2.2. Preclinical Studies

After analytical similarity is confirmed, preclinical studies are performed. These include in vitro experiments to assess biological activity, help evaluate safety, guide dose selection, and reduce risks before clinical trials.

2.3. Clinical Studies

Clinical trials are conducted to confirm similarity in human subjects.

- Usually performed in Phase I and Phase III, depending on regulatory requirements.

- Evaluate pharmacokinetics (PK), pharmacodynamics (PD), safety, efficacy, and immunogenic response.

2.4. Post-Marketing Surveillance (Additional Requirement)

Even after approval, continuous monitoring is essential.

- Involves tracking long-term safety and identifying rare or unexpected adverse reactions.
- Ensures ongoing assessment of the benefit–risk balance after the product is introduced to the market (10).

3. Current Scenario of Biosimilars in India

India has developed into one of the most rapidly expanding and significant markets for biosimilars worldwide.

3.1 Market Size and Growth

The biosimilars market is rapidly growing, driven by demand in cancer, diabetes, and autoimmune treatments. India is also a key exporter, supplying biosimilars to global markets.

3.2 Number of Approved Biosimilars in India

India has around 90-100+ approved biosimilars, making it a global leader. Approvals began in the early 2000s with products like the hepatitis B vaccine and increased significantly after structured guidelines were introduced in 2012 and later updated (13,14, 15).

4. Applications of Biosimilars

Biosimilars are extensively used in multiple therapeutic areas in India and worldwide (16, 17, 18).

Table 2: Applications Of Biosimilars

Sr. No.	Therapeutic Area	Medicine	Indications /Uses	Key Benefits
1.	Oncology	Trastuzumab, Rituximab,	Breast cancer; Blood cancers	Largest application area globally; biosimilars

		Bevacizumab	(lymphoma, leukemia)	reduce cost and improve access to therapy
2.	Autoimmune Disease	Adalimumab, Infliximab, Etanercept	Rheumatoid arthritis; Psoriasis; Crohn's disease	Supports long-term disease management at affordable cost
3.	Diabetes Management	Insulin glargine, Recombinant insulin products	Type 1 diabetes; Type 2 diabetes	Highly significant in India due to large diabetic population

4. Advantages of Biosimilars

Biosimilars offer a range of significant benefits to patients, healthcare systems, and the pharmaceutical industry.

4.1. Cost-effectiveness

Biosimilars offer high-quality treatment at a lower cost than original biologic drugs. Since they do not require full clinical trials like new biologics, their development is faster and less expensive, making treatments more affordable.

4.2. Improved Patient Access

Biosimilars help make advanced treatments more affordable, especially in low- and middle-income countries, allowing more patients to access proper care and reducing healthcare inequalities.

4.3. Reduced Healthcare Burden

Biosimilars help ease the overall burden on healthcare systems by lowering both direct treatment costs and indirect expenses linked to chronic disease management. Direct savings are achieved through reduced drug prices, while indirect benefits include better disease

4.4. Encouragement of Competition

Biosimilars boost market competition, reducing medicine prices and driving innovation. They encourage companies to improve efficiency and develop better therapies, while regulators like the FDA and European Medicines Agency help ensure biologic treatments remain affordable (19,20).

5. Challenges and Limitations

Biosimilars have greatly improved access to biologic medicines and helped lower overall healthcare expenses.

5.1. Manufacturing Complexity

A key limitation of biosimilars is the complexity of biologic drug production. Since biologics are made using living cells, even small changes in production or storage conditions can affect the final product.

5.2. Regulatory Hurdles

The approval process for biosimilars is complex and strict. Manufacturers must show close similarity to the original biologic through detailed testing, including laboratory studies, animal studies, and sometimes clinical trials.

5.3. Lack of Awareness Among Clinicians and Patients

A key challenge with biosimilars is limited awareness and misconceptions among doctors and patients. Concerns about safety and effectiveness make doctors cautious, while patients often mistakenly believe biosimilars are low-quality or simple generics.

5.4. Pharmacovigilance Issues

Pharmacovigilance is essential for biosimilars but faces challenges like traceability. It can be difficult to identify whether a patient received the original biologic or a biosimilar, requiring proper naming and accurate record-keeping.

5.5. Patent and Legal Barriers

Intellectual property rights and legal barriers can delay biosimilar entry into the market. Multiple secondary patents, known as “patent thickets,” protect original biologics and can slow down biosimilar development even after the main patent expires.

6. Future Perspectives of Biosimilars

The future of biosimilars is promising due to rising demand for affordable treatments, increasing chronic diseases, and ongoing improvements in regulations and industry practices.

6.1. Growth Opportunities in India

India is a fast-growing biosimilar market due to high disease burden and demand for affordable treatments. With strong production capacity and support from the CDSCO, the country is emerging as a major global hub for biosimilars.

6.2 Government Initiatives (Make in India)

The Make in India program supports biosimilar growth by encouraging local production and reducing imports, with help from Biotechnology Industry Research Assistance Council and Department of Biotechnology through funding and infrastructure support.

6.3. Export Potential

India has strong biosimilar export potential due to low-cost manufacturing and compliance with standards from the World Health Organization, European Medicines Agency, and FDA, helping expand affordable treatments globally.

6.4. Development of Biobetters

Biobetters are improved versions of existing biologic drugs designed to enhance features like longer action, reduced immune reactions, better effectiveness, and more convenient dosing, unlike biosimilars which are copies of original biologics.

6.5. Role of Technology (AI and Personalized Medicine)

AI improves manufacturing by optimizing cell line selection, predicting protein structures, and ensuring consistent production. It also enhances clinical trials by identifying suitable patients and accurately assessing immune response risks (20, 21).

7. Conclusion

Biosimilars are changing the Indian healthcare system by making life-saving biologic therapies much cheaper and easier to get. India has made it easier for high-quality biosimilars to be developed and approved by setting up a strong regulatory framework through the Central Drugs Standard Control Organization (CDSCO) and providing strategic policy and scientific support through the Department of Biotechnology (DBT).

These improvements have made it easier for more people to get important treatments for chronic and life-threatening conditions like cancer, diabetes, and autoimmune diseases. This has made things less expensive for both patients and the healthcare system. Also, Indian pharmaceutical companies are actively involved in biosimilar innovation and production, which has made the country a stronger player in the global biopharmaceutical market.

In the future, it will be very important to keep investing in research and development, make pharmacovigilance systems stronger, and make sure that regulations are in line with global standards. Another important factor in getting more people to accept biosimilars is making sure that both healthcare professionals and patients know how safe and effective they are.

In conclusion, biosimilars are not only a cheaper option than biologics, but they also have a lot of potential to change the future of healthcare in India by making it more fair, accessible, and long-lasting.

8. References

1. World Health Organization. Guidelines on evaluation of similar biotherapeutic products. Geneva: WHO; 2009.

2. European Medicines Agency. Biosimilars in the EU: information guide. London: EMA; 2020.

3. World Health Organization. Noncommunicable diseases country profile: India. Geneva: WHO; 2022.

4. Indian Council of Medical Research. India: health of the nation's states report. New Delhi: ICMR; 2017.
5. European Medicines Agency. Guideline on similar biological medicinal products. London: EMA; 2014.
6. Central Drugs Standard Control Organization. Guidelines on similar biologics. New Delhi: CDSCO; 2019.
7. Department of Biotechnology. Regulatory guidelines for similar biologics. New Delhi: DBT; 2016.
8. Central Drugs Standard Control Organization. List of approved similar biologics in India. New Delhi: CDSCO; 2023.
9. Indian Council of Medical Research. Cancer and diabetes treatment guidelines. New Delhi: ICMR; 2022.
10. Biocon Ltd, Dr. Reddy's Laboratories Ltd, Zydus Lifesciences Ltd. Company product monographs. India; 2024–2025.
11. Biocon Biologics. Product portfolio data. Bengaluru: Biocon Biologics; 2023–2024.
12. Dr. Reddy's Laboratories. Biosimilar pipeline information. Hyderabad: Dr. Reddy's Laboratories; 2024–2025.
13. Pharma Outlook, 6W Research. India biosimilars market analysis reports. 2020–2025.
14. Biosimilars in India: current status and future perspectives. PMCID/PMC. 2021–2022.
15. European League Against Rheumatism. Position statements on biosimilars. EULAR; 2022.
16. IQVIA Institute. The impact of biosimilars on healthcare systems. IQVIA; 2023.
17. Blackstone EA, Fuhr JP. The economics of biosimilars. Am Health Drug Benefits. 2013;6(8):469–478.
18. U.S. Food and Drug Administration. Biosimilars action plan: 2018–2023 updates. Silver Spring (MD): FDA; 2023.
19. World Health Organization. Guidelines on evaluation of similar biotherapeutic products. Geneva: WHO; 2019.
20. World Health Organization. Guidelines on similar biotherapeutic products and global access strategies. Geneva: WHO; 2019–2023.
21. Central Drugs Standard Control Organization. Guidelines on similar biologics in India: updated framework. New Delhi: CDSCO; 2016.